The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...
The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with ...
The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...
The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.
Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...
Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.
The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.
MedPage Today on MSN7h
Good News for CAR-T Therapy; Liquid Biopsy Progress; Anti-Psychotic for Brain CancerBriaCell Therapeutics announced that its Bria-IMT cell therapy, plus an immune checkpoint inhibitor regimen, achieved ...
Bristol Myers Squibb has received FDA approval for Opdivo (nivolumab) combined with chemotherapy as a perioperative treatment ...
In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) cleared Opdivo (nivolumab) for use with platinum-based chemo to reduce the size ...
Medpage Today on MSN2d
De-Intensified Therapy Misses Mark in HPV-Positive Oropharyngeal CancerTwo strategies to de-escalate treatment for human papillomavirus (HPV)-positive oropharyngeal cancer failed to show ...
No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback